JP Patent

JP2018127473A — 抗ウイルス療法

Assigned to ViiV Healthcare Co · Expires 2018-08-16 · 8y expired

What this patent protects

【課題】ＨＩＶ感染の治療に有用な新規組み合わせ医薬の提供。【解決手段】リルピビリン又はその薬学上許容される塩と、下記式（ＩＩ）で表される化合物又はその薬学上許容される塩とを含む医薬組成物。【選択図】なし

USPTO Abstract

【課題】ＨＩＶ感染の治療に有用な新規組み合わせ医薬の提供。【解決手段】リルピビリン又はその薬学上許容される塩と、下記式（ＩＩ）で表される化合物又はその薬学上許容される塩とを含む医薬組成物。【選択図】なし

Drugs covered by this patent

Patent Metadata

Patent number: JP2018127473A
Jurisdiction: JP
Classification: —
Expires: 2018-08-16
Drug substance claim: No
Drug product claim: No
Assignee: ViiV Healthcare Co
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.